Comparative Study of Ceftaroline vs. Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin Infections (cSSSI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.

ClinicalTrials.gov Identifier: NCT00424190

Recruitment Status : Completed

First Posted : January 18, 2007

Results First Posted : November 8, 2010

Last Update Posted : March 14, 2017

Sponsor:

Information provided by:

Forest Laboratories

Study Description

Brief Summary:

The purpose of this study is to determine whether ceftaroline is effective and safe in the treatment of complicated skin infections in adults.

Condition or disease	Intervention/treatment	Phase
Bacterial Infections	Drug: IV Vancomycin plus IV Aztreonam Drug: Ceftaroline	Phase 3

Detailed Description:

Additional purpose of the study is to compare ceftaroline effectivity versus Vancomycin plus Aztreonam in the treatment of complicated skin infections in adults.

Study Design


Study Type :	Interventional (Clinical Trial)
Actual Enrollment :	698 participants
Allocation:	Randomized
Intervention Model:	Parallel Assignment
Masking:	Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:	Treatment
Official Title:	A Phase 3, Multicenter, Randomized, Double-blind, Comparative Study to Evaluate the Safety and Efficacy of Ceftaroline Versus Vancomycin Plus Aztreonam in Adult Subjects With Complicated Skin and Skin Structure Infection
Study Start Date :	February 2007
Actual Primary Completion Date :	November 2007
Actual Study Completion Date :	November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Skin Infections

Drug Information available for: Vancomycin Vancomycin hydrochloride Aztreonam Ceftaroline Ceftaroline fosamil

U.S. FDA Resources

Arms and Interventions

Arm	Intervention/treatment
Experimental: Ceftaroline for Injection	Drug: Ceftaroline 600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days Other Name: Experimental
Active Comparator: IV Vancomycin and IV Aztreonam	Drug: IV Vancomycin plus IV Aztreonam vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days. Other Name: Active Comparator

Outcome Measures

Primary Outcome Measures :

Clinical Cure Rate at Test of Cure (TOC) (MITT Population) [ Time Frame: 8-15 days after the end of treatment ]
Cure: Total resolution of all signs and symptoms of the baseline infection, or improvement of the infection such that no further antimicrobial therapy was necessary.

Failure: Requirement of alternative antimicrobial therapy for primary infection of cSSSI due to inadequate response, recurrence, new infection at the same site; treatment-limiting adverse event (AE); requirement for surgery due to failure of study drug; diagnosis of osteomyelitis after Study Day 8; or death caused by cSSSI.

Indeterminate: Inability to determine an outcome
Clinical Cure Rate of Ceftaroline Compared With That of Vancomycin Plus Aztreonam Treatment at TOC in the Clinically Evaluable (CE) Population [ Time Frame: 8-15 days after last dose of study drug ]

Secondary Outcome Measures :

Microbiological Success Rate at the TOC Visit [ Time Frame: 8-15 days after last dose of study drug ]
Clinical Response at the End of Therapy (EOT) Visit [ Time Frame: Last day of study drug administration ]
Clinical and Microbiological Response by Pathogen at the TOC Visit [ Time Frame: 8-15 days after last dose of study drug ]
Clinical Relapse at the Late Follow Up (LFU) Visit [ Time Frame: 21 to 35 days after the last dose of study drug ]
Microbiological Reinfection or Recurrence at the LFU Visit [ Time Frame: 21 to 35 days after the last dose of study drug ]
Assess Safety [ Time Frame: First dose of study drug through TOC visit ]
Comparisons of the number of participants with Adverse Events

Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Skin and skin structure infection (SSSI) that involves deeper soft tissue or requires significant surgical intervention, or cellulitis or abscess on lower extremity which occurs in subjects with diabetes mellitus or well-documented peripheral vascular disease.

Exclusion Criteria:

Prior treatment of current cSSSI with an antimicrobial.
Failure of vancomycin or aztreonam as therapy for the current cSSSI, or prior isolation of an organism with in vitro resistance to vancomycin or aztreonam.

Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00424190

Show 52 Study Locations

Sponsors and Collaborators

Forest Laboratories

Investigators


Principal Investigator:	Ralph Corey, MD	Duke University

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv67-iv71. doi: 10.1093/jac/dkq256.

Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010 Nov;65 Suppl 4:iv41-51. doi: 10.1093/jac/dkq254.

Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010 Sep 15;51(6):641-50. doi: 10.1086/655827.


Responsible Party:	Senior Vice President, Clinical Development, Cerexa, Inc
ClinicalTrials.gov Identifier:	NCT00424190 History of Changes
Other Study ID Numbers:	P903-06
First Posted:	January 18, 2007 Key Record Dates
Results First Posted:	November 8, 2010
Last Update Posted:	March 14, 2017
Last Verified:	February 2017

Keywords provided by Forest Laboratories:


Abscess Antibacterial Antibiotic Antimicrobial Bacterial infection, skin Ceftaroline Ceftaroline acetate Cellulitis Cephalosporin Complicated skin and skin structure infection cSSSI	Intravenous Methicillin-resistant Staphylococcus Aureus (MRSA) PPI-0903 Prodrug Skin disease, bacterial Skin infection Staphylococcal skin infection Staphylococcus aureus Streptococcal skin infection Surgical site infection TAK-599

Additional relevant MeSH terms:


Infection Communicable Diseases Bacterial Infections Skin Diseases, Infectious Skin Diseases	Vancomycin Cephalosporins Aztreonam Anti-Bacterial Agents Anti-Infective Agents

To Top